Sleep Initiation and Maintenance Disorders: Shapiro CM

Saleh P, Shapiro CM. · No affiliation provided · J Psychosom Res. · Pubmed #18582605 No free full text.

This publication has no abstract.

Ohayon MM, Shapiro CM. · No affiliation provided · J Psychosom Res. · Pubmed #12127167 No free full text.

This publication has no abstract.

Novak M, Shapiro CM, Mendelssohn D, Mucsi I. · Institute of Behavioral Sciences, Semmelweis University, Budapest, Hungary, and Department of Nephrology, Humber River Regional Hospital, Toronto, Ontario, Canada. · Semin Dial. · Pubmed #16423179 No free full text.

Abstract: Sleep-related complaints affect 50-80% of patients on dialysis. Sleep disorders impair quality of life significantly. Increasing evidence suggests that sleep disruption has a profound impact both on an individual and on a societal level. The etiology of sleep disorders is often multifactorial: biologic, social, and psychological factors play a role. This is especially true for insomnia, which is the most common sleep disorder in different populations, including patients on dialysis. Biochemical and metabolic changes, lifestyle factors, depression, anxiety, and other underlying sleep disorders can all have an effect on the development and persistence of sleep disruption, leading to chronic insomnia. Insomnia is defined as difficulty initiating or maintaining sleep, or having nonrestorative sleep. It is also associated with daytime consequences, such as sleepiness and fatigue, and impaired daytime functioning. In most cases, the diagnosis of insomnia is based on the patient's history, but in some patients objective assessment of sleep pattern may be necessary. Optimally the treatment of insomnia involves the combination of both pharmacologic and nonpharmacologic approaches. In some cases acute insomnia resolves spontaneously, but if left untreated, it may lead to chronic sleep problems. The treatment of chronic insomnia is often challenging. There are only a few studies specifically addressing the management of this sleep disorder in patients with chronic renal disease. Considering the polypharmacy and altered metabolism in this patient population, treatment trials are clearly needed. This article reviews the diagnosis of sleep disorders with a focus on insomnia in patients on dialysis.

Moller HJ, Barbera J, Kayumov L, Shapiro CM. · Department of Psychiatry, Sleep and Alertness Clinic, Toronto Western Hospital, University of Toronto, 399 Bathurst St, Toronto, Ont. M5T-2S8, Canada. · Sleep Med Rev. · Pubmed #15062209 No free full text.

Abstract: Epidemiological trends towards a 'graying' population make the issue of insomnia in the elderly an increasingly important research and clinical topic. It is often challenging to determine how much of a psychiatric dimension there is to a clinical condition that is best viewed as both as a symptom and a true psychosomatic entity in its own right. To categorize insomnia as either psychiatric or medically based risks oversimplification of the complexities of sleep disruption in the elderly. Normal senescence-related changes in sleep architecture and circadian rhythms must be considered, as well as the frequent medical comorbidities that may affect sleep. Psychiatric diagnoses to consider include mood and anxiety disorders, which may be affected equally by physiological and psychological changes implicit in old age. Sleep disruption related to dementia is of particular interest to clinicians involved with patients in long-term care facilities. Insomnia may occasionally be iatrogenically induced or exacerbated, and particularly antidepressants must be carefully selected for this reason. Light therapy and behavior therapies are important in multimodal treatment of insomnia, and sleep hygiene includes both regular physical and social activities to preserve entrainment of circadian rhythms affecting sleep.

Montplaisir J, Hawa R, Moller H, Morin C, Fortin M, Matte J, Reinish L, Shapiro CM. · Department of Psychiatry, University of Toronto, ECW-3D Bathurst Street, Toronto, Ontario M5T 2SB, Canada. · Hum Psychopharmacol. · Pubmed #12532313 No free full text.

This publication has no abstract.

Shen J, Chung SA, Kayumov L, Moller H, Hossain N, Wang X, Deb P, Sun F, Huang X, Novak M, Appleton D, Shapiro CM. · Department of Psychiatry, University Health Network, University of Toronto, Toronto, Ontario. · Can J Psychiatry. · Pubmed #16491981 No free full text.

Abstract: OBJECTIVE: This study aimed to characterize the effects of mirtazapine on polysomnographic sleep, especially slow wave sleep (SWS) and rapid eye movement (REM) sleep, as well as its effects on clinical symptoms in patients with major depressive disorder (MDD). METHOD: Sixteen MDD patients were treated with mirtazapine 30 mg taken 30 minutes before bedtime. Polysomnographic and subjective sleep, as well as other clinical data, were collected at baseline and on Days or Nights 2, 9, 16, 30, and 58 during treatment. We used repeated measures analysis of variance, including pairwise comparison, to analyze data statistically. RESULTS: Mirtazapine administration increased total SWS and the SWS in the first sleep cycle, but not SWS in the second sleep cycle. The medication increased REM latency and the duration of the first REM episode; it also decreased the number of REM episodes. Simultaneously, mirtazapine significantly reduced wake-after-sleep onset and scores on the Athens Insomnia Scale. After patients took the medication, scores on the Hamilton Depression Rating Scale-17 (HDRS-17) decreased rapidly and continuously. The changes on the Beck Depression Inventory-II were consistent with those on the HDRS-17. The medication has a tendency to increase weight. CONCLUSIONS: Mirtazapine significantly improved sleep quality, reversed sleep markers of depression, and reduced depressive symptoms in this group of MDD patients.

Spence DW, Kayumov L, Chen A, Lowe A, Jain U, Katzman MA, Shen J, Perelman B, Shapiro CM. · Centre for Addiction and Mental Health, Toronto, Ontario, Canada. · J Neuropsychiatry Clin Neurosci. · Pubmed #14990755 links to  free full text

Abstract: The response to acupuncture of 18 anxious adult subjects who complained of insomnia was assessed in an open prepost clinical trial study. Five weeks of acupuncture treatment was associated with a significant (p = 0.002) nocturnal increase in endogenous melatonin secretion (as measured in urine) and significant improvements in polysomnographic measures of sleep onset latency (p = 0.003), arousal index (p = 0.001), total sleep time (p = 0.001), and sleep efficiency (p = 0.002). Significant reductions in state (p = 0.049) and trait (p = 0.004) anxiety scores were also found. These objective findings are consistent with clinical reports of acupuncture's relaxant effects. Acupuncture treatment may be of value for some categories of anxious patients with insomnia.

Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. · Department of Psychiatry, University of Toronto, and University Health Network, Toronto Western Hospital, Ontario, Canada. · Psychosom Med. · Pubmed #11211063 links to  free full text

Abstract: OBJECTIVE: The effects of exogenous melatonin on sleep, daytime sleepiness, fatigue, and alertness were investigated in 22 patients with delayed sleep phase syndrome whose nocturnal sleep was restricted to the interval from 24:00 to 08:00 hours. This study was a randomized, double-blind, placebo-controlled crossover trial. Subjects received either placebo or melatonin (5 mg) daily for 4 weeks, underwent a 1-week washout period, and then were given the other treatment for an additional 4 weeks. Patients could take the melatonin between 19:00 and 21:00 hours, which allowed them to select the time they felt to be most beneficial for the phase-setting effects of the medication. METHODS: Two consecutive overnight polysomnographic recordings were performed on three occasions: at baseline (before treatment), after 4 weeks of melatonin treatment, and after 4 weeks of placebo treatment. RESULTS: In the 20 patients who completed the study, sleep onset latency was significantly reduced while subjects were taking melatonin as compared with both placebo and baseline. There was no evidence that melatonin altered total sleep time (as compared with baseline total sleep time), but there was a significant decrease in total sleep time while patients were taking placebo. Melatonin did not result in altered scores on subjective measures of sleepiness, fatigue, and alertness, which were administered at different times of the day. After an imposed conventional sleep period (from 24:00 to 08:00), subjects taking melatonin reported being less sleepy and fatigued than they did while taking placebo. CONCLUSIONS: Melatonin ameliorated some symptoms of delayed sleep phase syndrome, as confirmed by both objective and subjective measures. No adverse effects of melatonin were noted during the 4-week treatment period.

Trajanovic NN, Radivojevic V, Kaushansky Y, Shapiro CM. · Sleep and Alertness Clinic, University Health Network, Fell 3B-178, 399 Bathurst Street, Toronto, Ont., Canada M5T 2S8. · Sleep Med. · Pubmed #17275407 No free full text.

Abstract: OBJECTIVES: To better define the concept of sleep misperception and analyse a category of patients who overestimate their sleep. At present, a condition of underestimation of sleep is classified as paradoxical insomnia. Overestimation of sleep has also been reported in the past, with no clear reference to corresponding polysomnographic (PSG) findings or its clinical significance. PATIENTS AND METHODS: Patients were recruited from the general population undergoing a PSG assessment for a cross-sectional retrospective study in a sleep clinic affiliated with a tertiary health center. RESULTS: A group of patients who overestimated their sleep had mostly non-discriminating PSG findings when compared to patients who underestimated their sleep, and correct estimators. The only parameters that were significantly different were objective sleep duration and efficiency, and, importantly, respective multiple sleep latency test (MSLT) results. The patients who overestimated their sleep had a mean MSLT result of 7.8 min, which indicates moderate daytime sleepiness. Patients who underestimated their sleep and correct estimators had the respective MSLT results of >10 min, making a statistically significant difference. CONCLUSION: The authors identified a condition opposite the previously described sleep underestimation, and named it 'positive sleep state misperception' (PSSM). The condition is characterised by a gross overestimation of sleep. Inadequate sleep results in a clinically significant excessive daytime sleepiness, which patients were not able to predict. The authors propose a new model that incorporates both ends of the sleep misperception spectrum.

Capua T, Shapiro CM. · Department of Psychiatry, University of Toronto, Toronto Western Hospital, Toronto, Canada. · J Psychopharmacol. · Pubmed #17213250 No free full text.

This publication has no abstract.

Moller HJ, Devins GM, Shen J, Shapiro CM. · Sleep Research Unit, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada, M5T-2S8. · Exp Brain Res. · Pubmed #16633807 No free full text.

Abstract: The constructs "sleepiness" and "alertness" are often assumed to be reciprocal states of consciousness. This distinction is of increasing concern in relation to psychomotor performance tasks such as driving. We developed two separate subjective scales of alertness to complement existing sleepiness scales. Subjective sleepiness and alertness were compared in four groups of sleep-disordered patients. In a 175-patient cohort [25 narcoleptics and 50 each with sleep apnea, insomnia and periodic leg movement disorder (PLMD)], the Epworth Sleepiness Scale (ESS) was used to measure sleepiness while the Toronto Hospital Alertness Test (THAT) and ZOGIM Alertness Scale (ZOGIM-A) were used to measure alertness. Significant differences existed for sleepiness scores, with narcoleptics scoring highest on the ESS, followed by sleep apnea, with similar ESS scores for insomnia and PLMD. By contrast, alertness scores on both the THAT and ZOGIM-A did not differ significantly between the four groups. Sleepiness scores show a correlation of close to nil to alertness scores for the combined sleep disorder patient cohort, with the exception of insomnia patients, where a modest but significant inverse relationship was noted between sleepiness and alertness. Subjective states of impaired alertness and excessive sleepiness are independent constructs in the evaluation of sleep-disordered patients. The specific primary sleep disorder diagnosis may play a relevant role in mitigating this interrelationship.

Novak M, Molnar MZ, Ambrus C, Kovacs AZ, Koczy A, Remport A, Szeifert L, Szentkiralyi A, Shapiro CM, Kopp MS, Mucsi I. · Institute of Behavioral Sciences, First Department of Internal Medicine, Semmelweis University, Budapest, Hungary. · Am J Kidney Dis. · Pubmed #16564943 No free full text.

Abstract: BACKGROUND: Recent studies confirmed that sleep disorders have a significant impact on various aspects of health in patients at different stages of chronic kidney disease. At the same time, there is an almost complete lack of information on the prevalence and correlates of insomnia in kidney transplant recipients. METHODS: In a cross-sectional study, the Athens Insomnia Scale was used to assess the prevalence of insomnia in a large sample of kidney transplant recipients compared with wait-listed dialysis patients and also a matched group obtained from a nationally representative sample of the Hungarian population. RESULTS: The prevalence of insomnia was 15% in wait-listed patients, whereas it was only 8% in transplant recipients (P < 0.001), which, in turn, was not different from the prevalence of this sleep problem in the sample of the general population (8%). Prevalences of insomnia in the transplant group were 5%, 7%, and 14% for the groups with glomerular filtration rates (GFRs) greater than 60 mL/min (> 1.00 mL/s), 30 to 60 mL/min (0.50 to 1.00 mL/s), and less than 30 mL/min (< 0.5 mL/s), respectively (P < 0.01). However, estimated GFR was no longer associated significantly with insomnia in the transplant population after statistical adjustment for several covariates. In a multivariate model, insomnia was significantly and independently associated with treatment modality (transplantation versus wait listing), as well as the presence of depression, restless legs syndrome, and high risk for obstructive sleep apnea syndrome, and with self-reported comorbidity. CONCLUSION: The prevalence of insomnia was substantially less in the transplant group than in wait-listed dialysis patients and similar to that observed in the general population. Because this condition potentially is treatable, attention should be directed to the appropriate diagnosis and management of insomnia in the kidney transplant recipient population.

Novak M, Mucsi I, Shapiro CM, Rethelyi J, Kopp MS. · Department of Psychiatry, University Health Network, University of Toronto, Toronto, Canada. · J Psychosom Res. · Pubmed #15172209 No free full text.

Abstract: OBJECTIVES: Epidemiological data describing the prevalence of sleep complaints in Hungary and its region are lacking; furthermore, limited information is available on health care use by individuals with sleep complaints. We assessed the prevalence of sleep complaints, insomnia in particular, in a nationally representative sample of the Hungarian population and assessed health care utilization by insomniacs. METHODS: Cross-sectional study, enrolling a nationally representative sample (N=12,643) of the adult Hungarian population. A battery of questionnaires was administered during a home interview. The Athens Insomnia Scale (AIS), additional questions on sleep behavior, as well as questions on current medical therapy for somatic and mental disorders were included in the battery of questionnaires administered. Psychosocial and demographic characteristics were also tabulated. RESULTS: Forty-seven percent of the sample reported at least one complaint related to sleep. Based on the AIS we report a 9% prevalence of insomnia in the total sample. Sleep deprivation was highly prevalent in the younger and middle-aged groups. The frequency of sleep problems increased with age. Individuals diagnosed with insomnia reported more frequent utilization of health services, including sick leave, emergency visits and hospitalization, than those without insomnia. CONCLUSION: Sleep complaints and sleep deprivation are frequent problems in the Hungarian population and are associated with increased health care utilization. The prevalence of insomnia in our sample was similar to what has been previously reported from other countries. The high prevalence of sleep-deprived individuals warrants further attention. Interventions that effectively improve insomnia may also reduce health care utilization by the affected individuals.

Brownlee K, Devins GM, Flanigan M, Fleming JA, Morehouse R, Moscovitch A, Plamondon J, Reinish L, Shapiro CM. · Department of Social Work, Lakehead University, Oliver Road, Thunder Bay, ON, Canada. · Hum Psychopharmacol. · Pubmed #12532317 No free full text.

Abstract: Gender differences in the prescribing patterns of general classes of medications for insomnia were examined. The classes of medications included: zopiclone, antidepressants, benzodiazepines, antihistamines and no medication. The sample comprised a sub-set of respondents from 2620 questionnaires of the Canadian Multicentre Sleep Database. Respondents for this database were contacted through physicians, announcements in the media and local pharmacies. The results indicated that gender alone was not associated with differential prescribing for insomnia, nor was gender associated with patterns of medication use such as frequency of taking medication, length of use, taking more or less medication than prescribed or attempts to stop taking medication. Demographic factors were included in the analysis and age and marital status were associated with different prescribing patterns for men and women with insomnia. It is possible that physicians refer to stereotypic expectations when prescribing hypnotics.